70
Participants
Start Date
January 20, 2025
Primary Completion Date
December 31, 2030
Study Completion Date
December 31, 2030
Sacituzumab govitecan
Sacituzumab govitecan is administered at 10 mg/kg as an intravenous (IV) infusion on Days 1 and 8 of a 21-day cycle.
Zimberelimab
ZIM is administered at 360 mg every 3 weeks as an intravenous (IV) infusion on Day 1 of a 21-day cycle.
Domvanalimab
DOM is administered at 1200 mg every 3 weeks as an intravenous (IV) infusion on Day 1 of a 21-day cycle.
RECRUITING
Hospital Clínico Universitario de Santiago, Santiago de Compostela
RECRUITING
ICO Badalona, Badalona
RECRUITING
Hospital Duran i Reynals (ICO L´Hospitalet), L'Hospitalet de Llobregat
RECRUITING
Hospital Universitario Marqués de Valdecilla, Santander
RECRUITING
Hospital Universitario Donostia, Donostia / San Sebastian
RECRUITING
Hospital Clínico San Carlos, Madrid
RECRUITING
Hospital Universitario de Navarra, Pamplona
RECRUITING
Hospital Virgen de la Salud, Toledo
RECRUITING
Fundación Instituto Valenciano de Oncología, Valencia
RECRUITING
Hospital Clinico Universitario de Valladolid, Valladolid
Apices Soluciones S.L.
INDUSTRY
Fundación para el Progreso de la Oncología en Cantabria
OTHER